Cargando…

Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents

Background and purpose: Previous studies have found that metformin can inhibit tumor growth and improve outcomes for cancer patients. However, the association between the addition of metformin to the treatment regimen and survival in non-small cell lung cancer (NSCLC) patients receiving antineoplast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yan, Hu, Yuanyuan, Wang, Ting, Che, Guowei, Li, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036803/ https://www.ncbi.nlm.nih.gov/pubmed/36969876 http://dx.doi.org/10.3389/fphar.2023.1123834

Ejemplares similares

Metformin Adjunct With Antineoplastic Agents for the Treatment of Lung Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Cohort Studies
por: Luo, Xiaofeng, et al.
Publicado: (2021)

Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease
por: Li, Xiao, et al.
Publicado: (2023)

Promising Antineoplastic Actions of Melatonin
por: Favero, Gaia, et al.
Publicado: (2018)

Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells
por: Cao, Nini, et al.
Publicado: (2020)

First use of antineoplastic agents in women with breast cancer in the state of Rio de Janeiro, Brazil
por: dos Santos, Ranailla Lima Bandeira, et al.
Publicado: (2023)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Development of the First Value Assessment Index System for Off-Label Use of Antineoplastic Agents in China: A Delphi Study
por: Jiang, Qian, et al.
Publicado: (2020)

Potentially Hazardous Drug-Drug Interactions Associated With Oral Antineoplastic Agents Prescribed in Chinese Tertiary Care Teaching Hospital Settings: A Multicenter Cross-Sectional Study
por: Wang, Haitao, et al.
Publicado: (2022)

Chloride intracellular channel 1 regulates the antineoplastic effects of metformin in gallbladder cancer cells
por: Liu, Yongchen, et al.
Publicado: (2017)

Systematic Transcriptome Analysis Reveals the Inhibitory Function of Cinnamaldehyde in Non-Small Cell Lung Cancer
por: Chen, Ru, et al.
Publicado: (2021)

Addition of metformin to non‐small‐cell lung cancer patients with or without diabetes
por: Chen, Hua‐Fen, et al.
Publicado: (2022)

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
por: Kou, Wen, et al.
Publicado: (2022)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model
por: Wang, Jiun-Long, et al.
Publicado: (2021)

The potential of metformin as an antineoplastic in brain tumors: A systematic review
por: Takhwifa, Famila, et al.
Publicado: (2021)

Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy
por: Gouveris, Panagiotis, et al.
Publicado: (2021)

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
por: Hu, Yan, et al.
Publicado: (2022)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

Antineoplastic and Immunosuppressive Agents—Part 1
por: Lajtha, L. G.
Publicado: (1975)

Extravasation of Antineoplastic Agents: Prevention and Treatments
por: Boschi, Rita, et al.
Publicado: (2012)

Antineoplastic Agents Targeting Sphingolipid Pathways
por: Kroll, Alexander, et al.
Publicado: (2020)

Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans
por: Rotroff, Daniel M., et al.
Publicado: (2016)

Development and Evaluation of Novel Metformin Derivative Metformin Threonate for Brain Ischemia Treatment
por: Zhang, Gufang, et al.
Publicado: (2022)

Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
por: Fu, Bingjie, et al.
Publicado: (2022)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

Targeting glycolysis in non-small cell lung cancer: Promises and challenges
por: Xu, Jia-Qi, et al.
Publicado: (2022)

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2022)

The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting
por: Herrero Fernandez, Marta, et al.
Publicado: (2019)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

Gold(III)–pyrrolidinedithiocarbamato Derivatives as Antineoplastic Agents**
por: Nardon, Chiara, et al.
Publicado: (2015)

Oral Antineoplastic Agents: Assessing the Delay in Care
por: Anders, Brandi, et al.
Publicado: (2015)

Computer-aided predictions of potential antineoplastic agents
por: Zakharov, Alexey, et al.
Publicado: (2008)

Design and Synthesis of Organic Molecules as Antineoplastic Agents
por: Boga, Carla, et al.
Publicado: (2020)

Neuropharmacological efficacy of metformin for stroke in rodents: A meta-analysis of preclinical trials
por: Fu, Wenqiao, et al.
Publicado: (2022)

An appraisal of the current status of inhibition of glucose transporters as an emerging antineoplastic approach: Promising potential of new pan-GLUT inhibitors
por: Temre, Mithlesh Kumar, et al.
Publicado: (2022)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
por: Lu, Tingting, et al.
Publicado: (2023)

Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review
por: Sun, Ruizheng, et al.
Publicado: (2019)

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer
por: Huang, Lu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_evm9shae4fo81pobugfuvt753g